Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for the Treatment of Traumatic Brain Injury III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe brain injury (GCS 12-4)~* Age 18 years or older~* Blunt, closed head injury~* Study drug initiated within 4 hours of injury~Exclusion Criteria:~* Non-Survivable injury~* Bilateral dilated unresponsive pupils~* Severe intoxication (ETOH \> 250 mg %)~* Spinal cord injury with neurological deficits~* Inability to perform activities of daily living prior to injury~* Cardiopulmonary arrest~* Status epilepticus on arrival~* Systolic blood pressure (SBP) \< 90 on arrival or for at least 5 minutes prior to enrollment~* O2 Sat \< 90 on arrival or for at least 5 minutes prior to enrollment~* Prisoner or ward of state~* Pregnant~* Active breast or reproductive organ cancers~* Known allergy to progesterone or intralipid components (egg yolk)~* Known history of clotting disorder~* Active thromboembolic event~* Concern for inability to follow up at 6 months~* Anyone listed in the Opt out registry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: EXPERIMENTAL): Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).